Side Effects of Multiple Sclerosis Medications
February 18, 2016
FDA Grants ‘Breakthrough Therapy’ Designation to Genentech’s Ocrelizumab for PPMS
February 19, 2016
Show all

Harvoni cleared for broader use in hepatitis C

The hepatitis C medication Harvoni has now been approved by the FDA to be used in liver transplant patients.

The FDA approved Harvoni (ledipasvir/sofosbuvir) for two new indications that will expand its use in liver transplant patients with HCV as well as those with decompensated cirrhosis, who generally have a poor prognosis and often go on to require a liver transplant.

Previously treatment options in these patients have been limited and often involved injectable and hard-to-tolerate interferon alpha therapy. Now they will be able to receive a 12-week, oral course of Harvoni, expanding the target patient population for a drug that brought in nearly $14bn in sales last year.

Specifically, the US regulator has approved Harvoni in combination with ribavirin chronic HCV genotype (GT) 1- or 4-infected liver transplant recipients without cirrhosis or with compensated cirrhosis, as well as for GT 1-infected patients with decompensated cirrhosis, including those who have received a liver transplant.

Gilead has been expanding the use of Harvoni as the drug starts to face competition from rival oral HCV therapies, including AbbVie’s Viekirax/Viekira Pak (ombitasvir/paritaprevir/ritonavir and dasabuvir) and Merck & Co’s recently-approved Zepatier (elbasvir/grazoprevir), which has undercut Harvoni on price.

Last November, the FDA approved Harvoni for expanded use in patients with genotype 4, 5, and 6 chronic HCV infections and in patients co-infected with HIV. It also cleared a 12-week Harvoni and ribavirin regimen as an alternate therapy to 24 weeks of Harvoni for treatment-experienced genotype 1 patients with cirrhosis.

Read Full Article: Harvoni cleared for broader use in hepatitis C – PMLiVE

Comments are closed.